Bisphosphonates for postmenopausal osteoporosis
Authors:
- Richard EastellRERichard Eastell
- Jennifer S. WalshJWJennifer S. Walsh
- Nelson B. WattsNWNelson B. Watts
- Ethel SirisESEthel Siris
Abstract
No abstract availableKeywords
Funding Information
- National Institute for Health and Care Research
This publication has 63 references indexed in Scilit:
- Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal OsteoporosisThe Journal of Clinical Endocrinology & Metabolism, 2010
- Zoledronic Acid and Clinical Fractures and Mortality after Hip FractureNew England Journal of Medicine, 2007
- Effects of risedronate on fracture risk in postmenopausal women with osteopeniaOsteoporosis International, 2007
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- Effect of Alendronate on Vertebral Fracture Risk in Women With Bone Mineral Density T Scores of −1.6 to −2.5 at the Femoral Neck: The Fracture Intervention TrialMayo Clinic Proceedings, 2005
- Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 2004
- Bone safety of long-term bisphosphonate treatmentCurrent Medical Research and Opinion, 2004
- Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal WomenNew England Journal of Medicine, 2004
- Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral DensityNew England Journal of Medicine, 2002
- Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal OsteoporosisNew England Journal of Medicine, 1990